Literature DB >> 3120695

Degradation of heparin proteoglycan in cultured mouse mastocytoma cells.

K G Jacobsson1, U Lindahl.   

Abstract

Pulse-labelling of mouse mastocytoma cell cultures, established from ascites fluid, with inorganic [35S]sulphate for 1 h yielded labelled heparin proteoglycan containing polysaccharide chains of Mr 60,000-100,000. After chase incubation for 24 h most of the 35S appeared in intracellular polysaccharide fragments similar in size to commercially available heparin, Mr 5000-25,000, as indicated by gel chromatography. Products isolated from cultures after 6 h of chase incubation consisted of partially degraded free polysaccharide chains and, in addition, residual proteoglycans that were of smaller size than the proteoglycans initially pulse-labelled. The polysaccharide chains released by alkali treatment from the residual chase-incubated proteoglycans were of the same size as the chains derived from proteoglycans after 1 h of pulse labelling. These results suggest that the intracellular degradation of heparin proteoglycan to polysaccharide fragments is initiated by release of intact polysaccharide chains, probably by action of a peptidase, and is pursued through cleavage of these chains by an endoglycosidase. An endoglucuronidase with stringent substrate specificity [Thunberg, Bäckström, Wasteson, Ogren & Lindahl (1982) J. Biol. Chem. 257, 10278-10282] has previously been implicated in the latter step. Cultures of more purified mastocytoma cells (essentially devoid of macrophages) did not metabolize [35S]heparin proteoglycan to polysaccharide fragments, but instead accumulated free intact polysaccharide chains, i.e. the postulated intermediate of the complete degradation pathway. When such purified cells were co-cultured with adherent mouse peritoneal cells, presumably macrophages, formation of polysaccharide fragments was observed. It is tentatively proposed that the expression of endoglucuronidase activity by the mast cells depends on collaboration between these cells and macrophages.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3120695      PMCID: PMC1148290          DOI: 10.1042/bj2460409

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  27 in total

1.  THE ROLE OF SERINE IN THE LINKAGE OF HEPARIN TO PROTEIN.

Authors:  U LINDAHL; J A CIFONELLI; B LINDAHL; L RODEN
Journal:  J Biol Chem       Date:  1965-07       Impact factor: 5.157

2.  Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration.

Authors:  L O Andersson; T W Barrowcliffe; E Holmer; E A Johnson; G E Sims
Journal:  Thromb Res       Date:  1976-12       Impact factor: 3.944

3.  The separation of active and inactive forms of heparin.

Authors:  L H Lam; J E Silbert; R D Rosenberg
Journal:  Biochem Biophys Res Commun       Date:  1976-03-22       Impact factor: 3.575

4.  Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin.

Authors:  M Höök; I Björk; J Hopwood; U Lindahl
Journal:  FEBS Lett       Date:  1976-07-01       Impact factor: 4.124

5.  Formation of anhydrosugars in the chemical depolymerization of heparin.

Authors:  J E Shively; H E Conrad
Journal:  Biochemistry       Date:  1976-09-07       Impact factor: 3.162

6.  Purification and properties of bacterial chondroitinases and chondrosulfatases.

Authors:  T Yamagata; H Saito; O Habuchi; S Suzuki
Journal:  J Biol Chem       Date:  1968-04-10       Impact factor: 5.157

7.  Metabolism of macromolecular heparin in mouse neoplastic mast cells.

Authors:  S Ogren; U Lindahl
Journal:  Biochem J       Date:  1976-03-15       Impact factor: 3.857

8.  Degradation of heparin in mouse mastocytoma tissue.

Authors:  S Ogren; U Lindahl
Journal:  Biochem J       Date:  1971-12       Impact factor: 3.857

9.  Cleavage of macromolecular heparin by an enzyme from mouse mastocytoma.

Authors:  S Ogren; U Lindahl
Journal:  J Biol Chem       Date:  1975-04-10       Impact factor: 5.157

10.  Mass isolation and culture of rat kupffer cells.

Authors:  A C Munthe-Kaas; T Berg; P O Seglen; R Seljelid
Journal:  J Exp Med       Date:  1975-01-01       Impact factor: 14.307

View more
  8 in total

1.  Metabolic properties of a homogeneous proteoglycan of a haemopoietic stem cell line, FDCP-mix.

Authors:  A J Morris; T M Dexter; J T Gallagher
Journal:  Biochem J       Date:  1989-06-01       Impact factor: 3.857

2.  Endothelial heparan sulphate: compositional analysis and comparison of chains from different proteoglycan populations.

Authors:  A Lindblom; L A Fransson
Journal:  Glycoconj J       Date:  1990       Impact factor: 2.916

3.  Implications of Heparanase on Heparin Synthesis and Metabolism in Mast Cells.

Authors:  Marco Maccarana; Juan Jia; Honglian Li; Xiao Zhang; Israel Vlodavsky; Jin-Ping Li
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

4.  Biosynthesis of heparin. Modulation of polysaccharide chain length in a cell-free system.

Authors:  K Lidholt; J Riesenfeld; K G Jacobsson; D S Feingold; U Lindahl
Journal:  Biochem J       Date:  1988-09-01       Impact factor: 3.857

5.  Proteoglycan synthesis in human erythroleukaemia (HEL) cells.

Authors:  B P Schick; S Senkowski-Richardson
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

6.  Stable heparin-producing cell lines derived from the Furth murine mastocytoma.

Authors:  R I Montgomery; K Lidholt; N W Flay; J Liang; B Vertel; U Lindahl; J D Esko
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

7.  Specific Non-Reducing Ends in Heparins from Different Animal Origins: Building Blocks Analysis Using Reductive Amination Tagging by Sulfanilic Acid.

Authors:  Pierre A J Mourier
Journal:  Molecules       Date:  2020-11-26       Impact factor: 4.411

Review 8.  Glycosaminoglycans: Carriers and Targets for Tailored Anti-Cancer Therapy.

Authors:  Aikaterini Berdiaki; Monica Neagu; Eirini-Maria Giatagana; Andrey Kuskov; Aristidis M Tsatsakis; George N Tzanakakis; Dragana Nikitovic
Journal:  Biomolecules       Date:  2021-03-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.